['essential hypertension']
['aprocitentan 5 mg', 'aprocitentan 10 mg', 'aprocitentan 25 mg', 'aprocitentan 50 mg', 'lisinopril 20 mg', 'placebo']

        Inclusion Criteria:

          -  Signed informed consent prior to any study-mandated procedure

          -  No contra-indication to stop (according to label) anti-hypertensive treatment(s) at
             screening

          -  Mild-to-moderate essential hypertension with or without ongoing anti-hypertensive
             treatment(s):

             -- Mean (of 5 measurements) sitting diastolic blood pressure (SiDBP) ≥ 90 to < 110
             mmHg measured by office blood pressure measurements (OBPM).

          -  Women of childbearing potential must have a negative pregnancy test and use of
             reliable methods of contraception

        Exclusion Criteria:

          -  Severe hypertension (grade 3): mean sitting systolic/diastolic BP (SiSBP/SiDBP;
             measured by OBPM) ≥ 180/110 mmHg, respectively.

          -  Secondary hypertension

          -  Known hypertensive retinopathy greater than Keith-Wagener Grade 2

          -  Myocardial infarction, percutaneous transluminal coronary angioplasty, or coronary
             artery bypass graft within 12 months prior to randomization

          -  Unstable angina within 6 months prior to randomization

          -  Heart failure New York Heart Association class III and IV

          -  Valvular defects (such as severe aortic or mitral valve disease) and/or
             hemodynamically relevant rhythm disturbances

          -  Clinical evidence of cerebrovascular insufficiency or a cerebrovascular accident
             within 6 months prior to randomization.

          -  Subjects working night shifts

          -  Body mass index < 20 kg/m2 or > 40 kg/m2

          -  Treatment with any medication which may affect BP (e.g., treatment of psychiatric
             diseases, ophthalmic preparations)

          -  Treatment with strong cytochrome P450 3A4 (CYP3A4) isoenzyme inhibitors or inducers

          -  Treatment with guanethidine and/or mineralocorticoid receptor antagonists within 1
             month prior to Screening (Visit 1)

          -  Treatment with another investigational treatment within 1 month prior to Screening
             (Visit 1)

          -  Any circumstances or conditions, which, in the opinion of the investigator, may affect
             full participation in the study or compliance with the protocol
      